Holen Sie sich die Stockscreener-App
18.61
1.12%
-0.21
Handel nachbörslich:
18.61
Schlusskurs vom Vortag:
$18.82
Offen:
$19.06
24-Stunden-Volumen:
442.76K
Relative Volume:
0.58
Marktkapitalisierung:
$905.98M
Einnahmen:
$109.79M
Nettoeinkommen (Verlust:
$-153.49M
KGV:
-5.7979
EPS:
-3.2098
Netto-Cashflow:
$-172.59M
1W Leistung:
+9.47%
1M Leistung:
-9.04%
6M Leistung:
+9.15%
1J Leistung:
+81.56%
1-Tages-Spanne:
$18.61
$19.40
1-Wochen-Bereich:
$17.34
$19.40
52-Wochen-Spanne:
$3.42
$30.00
Urogen Pharma Ltd Stock (URGN) Company Profile
Firmenname
Urogen Pharma Ltd
Sektor
Branche
Telefon
972 9 770 7601
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
18.61 | 916.20M | 109.79M | -153.49M | -172.59M | -3.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-06-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-19 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2024-08-22 | Eingeleitet | Guggenheim | Buy |
| 2023-02-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-27 | Eingeleitet | Berenberg | Buy |
| 2020-04-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-13 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-09 | Eingeleitet | National Securities | Neutral |
| 2019-05-30 | Eingeleitet | JP Morgan | Neutral |
| 2019-05-29 | Eingeleitet | Goldman | Neutral |
| 2019-01-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-04-04 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-11-15 | Bestätigt | Oppenheimer | Outperform |
| 2017-11-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
Alle ansehen
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
Trend Recap: Is UroGen Pharma Ltd a cyclical or defensive stock2026 Reactions & Weekly High Conviction Trade Ideas - baoquankhu1.vn
URGN SEC FilingsUrogen Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Why The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value Steady - Yahoo Finance
UroGen Pharma CMO Schoenberg sells $145k in shares - Investing.com
UroGen Pharma Ltd.Ordinary Shares (NQ: URGN - The Chronicle-Journal
UroGen Pharma Ltd (UR8.DU) Income Statement - Yahoo! Finance Canada
Behavioral Patterns of URGN and Institutional Flows - news.stocktradersdaily.com
Activity Recap: Will UroGen Pharma Ltd stock benefit from M AMarket Volume Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
URGN: D. Boral Capital Maintains Buy Rating with $33 Price Targe - gurufocus.com
Urogen Pharma's (URGN) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Hennion & Walsh Asset Management Inc. Boosts Stock Position in Urogen Pharma $URGN - MarketBeat
UroGen’s Zusduri shows 72% event-free rate at 24 months By Investing.com - za.investing.com
UroGen Pharma (URGN) Announces Positive Phase 3 Trial Results fo - gurufocus.com
UroGen’s Zusduri shows 72% event-free rate at 24 months - investing.com
Urogen Pharma Ltd. Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI - marketscreener.com
Bladder cancer drug kept 72.2% of responders event-free for 2 years - Stock Titan
URGN PE Ratio & Valuation, Is URGN Overvalued - Intellectia AI
Urogen Pharma $URGN Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Is UroGen Pharma Ltd a cyclical or defensive stockTrade Volume Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
SG Americas Securities LLC Purchases 220,264 Shares of Urogen Pharma $URGN - MarketBeat
Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ - openPR.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart.com
Veteran cancer researcher Mark joins Urogen Pharma to drive progress in urologic oncology - Traders Union
Forecast Cut: Can UroGen Pharma Ltd keep up with sector leaders2026 Retail Activity & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
UroGen Pharma Hits Day High with Strong 7.12% Intraday Surge - Markets Mojo
How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And Opportunities - Yahoo Finance
Live UroGen Pharma Ltd. (URGN) Technical Analysis - Traders Union
UroGen Pharma Ltd. (URGN) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
UroGen Pharma Ltd. (URGN) Stock Price Prediction for 2026, 2030-2040 - Traders Union
UroGen Pharma Ltd Stock (ISIN: IL0011408896) Faces Pressure Amid Clinical Setbacks and Cash Burn Con - AD HOC NEWS
URGN Stock Price, Quote & Chart | UROGEN PHARMA LTD (NASDAQ:URGN) - ChartMill
UroGen Pharma Ltd Stock (ISIN: IL0011408896) Faces Pressure Amid Biotech Sector Volatility - AD HOC NEWS
UroGen Pharma (URGN) Highlights Key Findings in Bladder Cancer R - GuruFocus
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence - The Manila Times
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report - GlobeNewswire
Bladder Cancer Patients Report Delayed Diagnosis and Gaps in Support - GlobeNewswire Inc.
Jobs Data: Is UroGen Pharma Ltd stock showing strong momentumMarket Volume Report & Consistent Profit Trading Strategies - baoquankhu1.vn
URGN (UroGen Pharma) NonCurrent Deferred Revenue : $0.0 Mil (As of Dec. 2025) - GuruFocus
How (URGN) Movements Inform Risk Allocation Models - Stock Traders Daily
URGN Technical Analysis & ETF Price Forecast - Intellectia AI
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
UroGen closes up 43% ahead of FDA decision on bladder cancer candidate - MSN
UroGen Pharma Q3 2025 Earnings Preview - MSN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
UroGen Pharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
UroGen grants 51,200 stock units to new hires backing cancer drugs - Stock Titan
JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN - MarketBeat
Assessing UroGen Pharma (URGN) Valuation After Recent Share Price Volatility - simplywall.st
Q1 EPS Estimates for Urogen Pharma Lifted by HC Wainwright - MarketBeat
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers - Seeking Alpha
Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Urogen Pharma Ltd-Aktie (URGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schoenberg Mark | Chief Medical Officer |
Feb 03 '26 |
Sale |
19.69 |
7,373 |
145,174 |
144,985 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):